Compare Illumina, Inc. (ILMN) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs NIO Inc. — how do they compare? Illumina, Inc. trades at $269.18 (market cap $39.95B), while NIO Inc. trades at $3.61 (market cap $8.62B). The key difference: Illumina, Inc. is far larger — about 4.6× NIO Inc.'s market cap, and Illumina, Inc. is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and NIO Inc. for 81 Days on average.
| ILMN | NIO | |
|---|---|---|
Market Cap | $39.95B | $8.62B |
Volume | 3,169,503 | 39,648,517 |
Sector | Health | Consumer Cyclical |
52-Week High | $293.69 | $7.46 |
52-Week Low | $91.00 | $3.37 |
Typical Hold Time | 83 Days | 81 Days |
Enterprise Value | $41.31B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
NIO trades at $3.54, up 1.72% today but near a 52-week low, with a bearish technical signal. Revenue grew to $87.49B in 2025, yet net losses persist at -$15.57B, though margins improved. Recent Q3 2026 deliveries rose 25.4%, and a strategic battery-swap partnership with Geely aims to expand network utilization, valued at $2.38B.
The outlook hinges on scaling profitability amid a brutal EV price war. Analysts see 76% upside to a $6.23 target, but high debt and cash burn pose risks. Sentiment is mixed, with news highlighting growth potential against competitive and macroeconomic headwinds in China.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
